Read what an Expert Panel recommends for using Blue Light Cystoscopy with Cysview to treat non-muscle invasive bladder cancer. The Expert Consensus Document, published by Nature Reviews Urology, is entitled, Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statment on optimal use in the USA — update 2018. Read the paper.
Experts on NMIBC publish consensus on Blue Light Cystoscopy with Cysview®
Implementing Blue Light Flexible Cystoscopy in Non-muscle Invasive Bladder Cancer Surveillance
A review paper on Blue Light Cystoscopy (BLC™) with Hexvix®/Cysview® with focus on the use in the office setting with flexible cystoscopes was published on July 5, 2019, in the peer-reviewed European Medical Journal.
With emerging data confirming similar clinical benefits for flexible BLC in the surveillance of non-muscle invasive bladder cancer (NMIBC) to its current use in rigid cystoscopy, the authors state that there is a clear opportunity for flexible BLC to assert a central role in the treatment paradigm. In a clinical study, around 1 in 5 confirmed malignancies were detected only by flexible BLC (p<0.0001)1 and the introduction of flexible BLC for routine surveillance post-TURBT is supported by consensus among bladder cancer specialists2.
1 Daneshmand S et al. Efficacy and safety of blue light flexible cystoscopy with Hexaminolevulinate (HAL) in the surveillance of bladder cancer: A phase III, comparative, multi-center study. J Urol. 2018 Dec 2. pii: S0022-5347(17)78004-4. doi:10.1016/j.juro.2017.11.096.
2 Lotan Y, Bivalacqua TJ, Downs T, et al. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA – Update 2018. Nat Rev Urol. 2019; pending. doi: 10.1038/s41585-019-0184-4. [Epub ahead of print].
Radio Interview Discusses Blue Light Cystoscopy
Upstate Medical University urologist Joseph Jacob, MD, took to the airwaves to explain how bladder tumors can be diagnosed using Blue Light Cystoscopy with Cysview in conjunction with traditional White Light Cystoscopy.
UConn Health Spotlights its BLC with Cysview Technology
UConn Health is promoting its use of Blue Light Cystoscopy with Cysview with an educational YouTube video. Watch it now.
Marcus Daly Memorial Hospital Features BLC with Cysview in its New State-of-the-Art Surgical Center
The Pacific Northwest now has Blue Light Cystoscopy with Cysview available in Hamilton, MT. Marcus Daly Memorial Hospital had the grand opening of its new state-of-the-art Surgical Center on Friday, April 26. This article, head of the surgery department, Dr. James J. Zubernis, discusses the importance of the technology being made available.
St. Mary Medical Center Announces Use of Blue Light Cystoscopy with Cysview
On April 25, 2019 KYW Newsradio ran a story about the availability of Blue Light Cystoscopy with Cysview at St. Mary Medical Center in Langhorne, PA. Read the story.
Survey of Bladder Cancer Patients Reveals Big Changes – Patients are Looking for Cysview® (hexaminolevulinate)
UroToday.com published the key results of a survey answered by 600 bladder cancer patients. The biggest take-aways were that, more than ever before, bladder cancer patients know about Blue Light Cystoscopy with Cysview and are selecting urologists and treatment facilities that offer it.
Local News Segment Airs on Miami TV
Yesterday in Miami, WPLG Local10 aired a segment spotlighting Mount Sinai MedicalCenter and Dr. AlanNieder’s use of Blue Light Cystoscopy with Cysview (hexaminolevulinate). Take a look at how this exciting information was shared in that local market. http://bit.ly/MtSinaiJan19
CBS NewsChannel5 Feature: Blue Light Cystoscopy with Cysview
Photocure Inc., is pleased to announce NewsChannel5, the CBS affiliate in Nashville, TN, USA has featured the story of Bladder Cancer Survivor Mary Beth Ballard Murray, who is coming up on her five years survivorship. She was treated at Vanderbilt Hospital in Nashville, TN, by Dr. Sam Chang who is the Patricia & Rodes Hart Endowed Chair of Urologic Surgery and Professor, Department of Urology, where she received a Blue Light Cystoscopy with Cysview for the management of her Bladder Cancer. Watch her story on the station website.
Enhanced cystoscopy (BLC™ with Cysview®) has an important role in the management of bladder cancer patients
New data on Urine Cytology in the management of bladder cancer patients is now published in the prestigious peer reviewed BJUI journal (British Journal of Urology International). The analysis shows that relying on Cytology alone, especially for high risk patients, would miss early detection and BCG unresponsiveness in NMIBC (non-muscle invasive bladder cancer).
The results are from further analysis of three published phase III studies. The analysis is of 1487 urine samples from 1375 patients, overall 615 tumors were detected correlating to 41% of the cytological specimens. Click here http://bit.ly/BLC-Urine-Cytology for the full the article.
“Based on analysis of contemporary data, the sensitivity of cytology for detecting High Grade and CIS (carcinoma in situ) tumors remains low. The data supports the use of enhanced cystoscopy techniques, such as BLC with Cysview, which I now use for both the surveillance and TURBT in many of my patients,” says Dr. Yair Lotan, Urology Professor Helen J. and Robert S. Strauss Professorship in Urology at University of Texas, South Western (UTSW) and lead author on the publication.